The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies.
Cytokine
Depression
Inflammation
SNRI
SSRI
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
15
07
2020
accepted:
31
10
2020
pubmed:
10
11
2020
medline:
21
10
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
Depression has the topmost prevalence of all psychiatric diseases. It is characterized by a high recurrence rate, disability, and numerous and mostly unclear pathogenic mechanisms. Besides the monoamine or the neurotrophic hypothesis of depression, the inflammatory mechanism has begun to be supported by more and more evidence. At the same time, the current knowledge about the standard treatment of choice, the selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs), is expanding rapidly, adding more features to the initial ones. This review summarizes the in vivo anti-inflammatory effects of SSRIs and SNRIs in the treatment of depression and outlines the particular mechanisms of these effects for each drug separately. In addition, we provide an overview of the inflammation-related theory of depression and the underlying mechanisms. SSRIs and SNRIs decrease the neuroinflammation through multiple mechanisms including the reduction of blood or tissue cytokines or regulating complex inflammatory pathways: nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), inflammasomes, Toll-like receptor 4 (TLR4), peroxisome proliferator-activated receptor gamma (PPARγ). Also, SSRIs and SNRIs show these effects in association with an antidepressant action. SSRIs and SNRIs have an anti-neuroinflammatory role which might contribute the antidepressant effect.
Identifiants
pubmed: 33164143
doi: 10.1007/s10787-020-00777-5
pii: 10.1007/s10787-020-00777-5
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Serotonin Uptake Inhibitors
0
Serotonin and Noradrenaline Reuptake Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-90Références
Alcocer-Gómez E, Casas-Barquero N, Williams M, Romero-Guillena S, Cañadas-Lozano D, Bullón P, Sánchez-Alcazar J, Navarro-Pando J, Cordero M (2017) Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in major depressive disorder. Pharmacol Res 121:114–121
pubmed: 28465217
Ambrósio G, Kaufmann F, Manosso L, Platt N, Ghisleni G, Rodrigues A, Rieger D, Kaster M (2018) Depression and peripheral inflammatory profile of patients with obesity. Psychoneuroendocrinology 91:132–141
pubmed: 29550676
Andersen J, Stuhr-Hansen N, Zachariassen L, Koldsø H, Schiøtt B, Strømgaard K, Kristensen A (2014) Molecular basis for selective serotonin reuptake inhibition by the antidepressant agent fluoxetine (Prozac). Mol Pharmacol 85:703–714
pubmed: 24516100
Arteaga-Henríquez G, Simon M, Burger B, Weidinger E, Wijkhuijs A, Arolt V et al (2019) Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME Consortium. Front Psychiatry 10:458
pubmed: 31354538
pmcid: 6630191
Bah T, Benderdour M, Kaloustian S, Karam R, Rousseau G, Godbout R (2011) Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression. Behav Brain Res 225:243–251
pubmed: 21824496
Bai S, Guo W, Feng Y, Deng H, Li G, Nie H et al (2019) Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry 91:21–32
pubmed: 31658959
Basterzi A, Aydemir Ç, Kisa C, Aksaray S, Tuzer V, Yazici K, Göka E (2005) IL-6 levels decrease with ssri treatment in patients with major depression. Hum Psychopharmacol 20:473–476
pubmed: 16158446
Bauer M, Pfennig A, Severus E, Whybrow P, Angst J, Möller H (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14:334–385
pubmed: 23879318
Benatti C, Alboni S, Blom J, Mendlewicz J, Tascedda F, Brunello N (2018) Molecular changes associated with escitalopram response in a stress-based model of depression. Psychoneuroendocrinology 87:74–82
pubmed: 29049934
Blair JA, Barford PA, Morar C, Pheasant AE, Hamon CG, Whitburn SB, Leeming RJ, Reynolds GP, Coppen A (1984) Tetrahydrobiopterin metabolism in depression. Lancet 2:163
pubmed: 6146057
Bondy B (2002) Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci 4:7–20
Carboni L, McCarthy D, Delafont B, Filosi M, Ivanchenko E, Ratti E, Learned S, Alexander R, Domenici E (2019) Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. Transl Psychiatry 9:182
pubmed: 31375659
pmcid: 6677721
Cassano P, Fava M (2002) Depression and public health: an overview. J Psychosom Res 53:849–857
pubmed: 12377293
Chen C, Yeh Y, Kuo S, Liang C, Ho P, Huang C, Yen C, Shyu J, Lu R, Huang S (2018) Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder. Psychoneuroendocrinology 87:108–118
pubmed: 29055264
Cowie A, Dittel B, Stucky C (2019) A novel sex-dependent target for the treatment of postoperative pain: the NLRP3 inflammasome. Front Neurol 10:662
Dai J, Pan JY, Liao N, Shi J, Zeng Q, Huang L, Chen LP (2020) Influence of miR-155 on behaviors of depression mice through regulating Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci 24:1398–1407
pubmed: 32096189
Dallé E, Daniels W, Mabandla M (2017) Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a parkinsonian rat model associated with depression. Behav Brain Res 316:189–196
pubmed: 27569183
Dantzer R, O’Connor J, Freund G, Johnson R, Kelley K (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56
pubmed: 18073775
pmcid: 2919277
DiSabato D, Quan N, Godbout J (2016) Neuroinflammation: the devil is in the details. J Neurochem 139:136–153
pubmed: 26990767
pmcid: 26990767
D’Mello C, Swain MG (2017) Immune-to-brain communication pathways in inflammation-associated sickness and depression. Curr Top Behav Neurosci 31:73–94
pubmed: 27677781
Dong C, Zhang J, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K (2016) Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 144:7–12
pubmed: 26892759
Duda W, Kubera M, Kreiner G, Curzytek K, Detka J, Głombik K, Ślusarczyk J, Basta-Kaim A, Budziszewska B, Lasoń W, Regulska M, Leśkiewicz M, Roman A, Zelek-Molik A, Nalepa I (2017) Suppression of pro-inflammatory cytokine expression and lack of anti-depressant-like effect of fluoxetine in lipopolysaccharide-treated old female mice. Int Immunopharmacol 48:35–42
pubmed: 28460354
Dunn A, Swiergiel A, Beaurepaire R (2005) Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29:891–909
pubmed: 15885777
Dwivedi Y (2009) Brain-derived neurotrophic factor: role in depression and suicide. Neuropsych Dis Treat 5:433–449
Eller T, Vasar V, Shlik J, Maron E (2008) Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmac Biol Psychiatry 32:445–450
Felger J, Lotrich F (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199–229
pubmed: 23644052
pmcid: 3741070
Fernandes J, Gupta G (2019) N-Acetylcysteine attenuates neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat. Behav Brain Res 364:356–365
pubmed: 30772427
Ferrari A, Somerville A, Baxter A, Norman R, Patten S, Vos T, Whiteford H (2012) Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 43:471–481
pubmed: 22831756
Fornaro M, Martino M, Battaglia F, Colicchio S, Perugi G (2011) Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsych Dis Treat 7:51–56
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet 392:1789–1858
Ghosh S, Choudhury S, Chowdhury O, Mukherjee S, Das A, Sain A, Gupta P, Adhikary A, Chattopadhyay S (2020) Inflammation-induced behavioral changes is driven by alterations in Nrf2-dependent apoptosis and autophagy in mouse hippocampus: role of fluoxetine. Cell Signal 68:109521
pubmed: 31881324
Gunasekara N, Noble S, Benfield P (1998) Paroxetine. Drugs 55:85–120
pubmed: 9463792
Gupta K, Gupta R, Bhatia M, Tripathi A, Gupta L (2017) Effect of agomelatine and fluoxetine on HAM-D score, serum brain-derived neurotrophic factor, and tumor necrosis factor-αlevel in patients with major depressive disorder with severe depression. J Clin Pharmacol 57:1519–1526
pubmed: 28833192
Hahn D, Stokes C, Kaiser R, Meyer M, Lammert F, Gruenhage F (2018) Antidepressant effects of direct-acting antivirals against hepatitis C virus—results from a pilot study. Eur J Clin Invest 48(12):e13024
pubmed: 30175442
Halaris A, Myint A, Savant V, Meresh E, Lim E, Guillemin G, Hoppensteadt D, Fareed J, Sinacore J (2015) Does escitalopram reduce neurotoxicity in major depression? J Psychiatr Res 66–67:118–126
pubmed: 26009299
Hao WZ, Li X, Zhang P, Chen J (2020) A review of antibiotics, depression, and the gut microbiome. Psychiatry Res 284:112691
pubmed: 31791704
Haroon E, Woolwine B, Chen X, Pace T, Parekh S, Spivey J et al (2014) IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 39:1777–1785
pubmed: 24481242
pmcid: 4023151
Hashimoto R, Nagatsu T, Ohta T, Mizutani M, Omura I (2004) Changes in the concentrations of tetrahydrobiopterin, the cofactor of tyrosine hydroxylase, in blood under physical stress and in depression. Ann N Y Acad Sci 1018:378–386
pubmed: 15240393
Ho P, Yeh Y, Huang S, Liang C (2015) A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram. Psychoneuroendocrinology 53:246–255
pubmed: 25647343
Holliday S, Benfield P (1995) Venlafaxine. Drugs 49:280–294
pubmed: 7729333
Hsueh W, Wyne K (2011) Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens 13:224–237
Jha M, Minhajuddin A, Gadad B, Greer T, Grannemann B, Soyombo A et al (2017) Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 78:105–113
pubmed: 28187400
pmcid: 6080717
Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813
pubmed: 17981670
pmcid: 2734868
Karpa K, Cavanaugh J, Lakoski J (2006) Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 8:361–376
Kelley N, Jeltema D, Duan Y, He Y (2019) The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci 20:3328
pmcid: 6651423
Kelly J, Kennedy P, Cryan J, Dinan T, Clarke G, Hyland N (2015) Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 9:392
pubmed: 26528128
pmcid: 4604320
Kennedy S, Lam R, McIntyre R, Tourjman S, Bhat V, Blier P, Hasnain M, Jollant F, Levitt A, MacQueen G, McInerney S, McIntosh D, Milev R, Müller D, Parikh S, Pearson N, Ravindran A, Uher R (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can J Psychiatry 61:540–560
pubmed: 27486148
pmcid: 4994790
Köhler C, Freitas T, Stubbs B, Maes M, Solmi M, Veronese N, de Andrade N, Morris G, Fernandes B, Brunoni A, Herrmann N, Raison C, Miller B, Lanctôt K, Carvalho A (2018) Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol 55:4195–4206
pubmed: 28612257
Köhler-Forsberg ON, Lydholm C, Hjorthøj C, Nordentoft M, Mors O, Benros M (2019) Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand 139:404–419
pubmed: 30834514
Konsman J, Parnet P, Dantzer R (2002) Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25:154–159
pubmed: 11852148
Lee B, Kim Y (2010) The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig 7:231
pubmed: 21253405
pmcid: 3022308
Lee Y, Yang Y, Huang P, Li W, Huang M, Kao C, Chen Y, Chen M (2015) Exercise suppresses COX-2 pro-inflammatory pathway in vestibular migraine. Brain Res Bull 116:98–105
pubmed: 26151770
Levine J, Barak Y, Chengappa K, Rapoport A, Rebey M, Barak V (1999) Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40:171–176
pubmed: 10559698
Li Z, Qi D, Chen J, Zhang C, Yi Z, Yuan C, Wang Z, Hong W, Yu S, Cui D, Fang Y (2013) Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the chinese patients with major depressive disorder: a prospective longitudinal study. Psychoneuroendocrinology 38:107–114
pubmed: 22683211
Li H, Lin S, Qin T, Li H, Ma Z, Ma S (2017) Senegenin exerts anti-depression effect in mice induced by chronic un-predictable mild stress via inhibition of NF-κB regulating NLRP3 signal pathway. Int Immunopharmacol 53:24–32
pubmed: 29031144
Lima Giacobbo B, Doorduin J, Klein H, Dierckx R, Bromberg E, de Vries E (2018) Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation. Mol Neurobiol 56:3295–3312
pubmed: 30117106
pmcid: 6476855
Liu B, Xu C, Wu X, Liu F, Du Y, Sun J, Tao J, Dong J (2015) Icariin exerts an antidepressant effect in an unpredictable chronic mild stress model of depression in rats and is associated with the regulation of hippocampal neuroinflammation. Neuroscience 294:193–205
pubmed: 25791226
Liu Y, Shen J, Xu L, Li H, Li Y, Yi L (2017) Ferulic acid inhibits neuro-inflammation in mice exposed to chronic unpredictable mild stress. Int Immunopharmacol 45:128–134
pubmed: 28213267
Loftis J, Huckans M, Morasco B (2010) Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 37:519–533
pubmed: 19944762
Lu M, Yang J, Geng F, Ding J, Hu G (2014) Iptakalim confers an antidepressant effect in a chronic mild stress model of depression through regulating neuro-inflammation and neurogenesis. Int J Neuropsychopharmacol 17:1501–1510
pubmed: 24621884
Lu Y, Ho C, Liu X, Chua A, Wang W, McIntyre R, Ho R (2017) Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression. PLoS One 12:e0186700
pubmed: 29049348
pmcid: 5648231
Lu Y, Xu X, Jiang T, Jin L, Zhao X, Cheng J, Jin X, Ma J, Piao H, Piao L (2019) Sertraline ameliorates inflammation in cums mice and inhibits TNF-α-induced inflammation in microglia cells. Int Immunopharmacol 67:119–128
pubmed: 30544065
Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, De Jonckheere C, Minner B, Raus J (1992) Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 22:45–53
pubmed: 1574566
Maes M, Meltzer H, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R (1995) Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 34:301–309
pubmed: 8550956
Martinez J, Garakani A, Yehuda R, Gorman J (2011) Proinflammatory and “resiliency” proteins in the CSF of patients with major depression. Depress Anxiety 29:32–38
pubmed: 21898706
Martín-Hernández D, Bris Á, MacDowell K, García-Bueno B, Madrigal J, Leza J, Caso J (2016) Modulation of the antioxidant nuclear factor (erythroid 2-derived)-like 2 pathway by antidepressants in rats. Neuropharmacology 103:79–91
pubmed: 26686388
Miller A, Raison C (2015) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22–34
Miller A, Haroon E, Raison C, Felger J (2013) Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 30:297–306
pubmed: 23468190
pmcid: 4141874
Morón J, Zakharova I, Ferrer J, Merrill G, Hope B, Lafer E et al (2003) Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 23:8480–8488
pubmed: 13679416
pmcid: 6740378
Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD (1999) Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 156:1000–1006
pubmed: 10401442
Müller N, Myint A, Schwarz M (2010) Inflammatory biomarkers and depression. Neurotox Res 19:308–318
pubmed: 20658274
Mutlu O, Gumuslu E, Ulak G, Celikyurt I, Kokturk S, Kır H, Akar F, Erden F (2012) Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice. Life Sci 91:1252–1262
pubmed: 23069580
O’Brien S, Scott L, Dinan T (2006) Antidepressant therapy and C-reactive protein levels. Br J Psychiatry 188:449–452
pubmed: 16648531
Ohgi Y, Futamura T, Kikuchi T, Hashimoto K (2013) Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 103:853–859
pubmed: 23262300
Pälvimäki E, Kuoppamäki M, Syvälahti E, Hietala J (1999) Differential effects of fluoxetine and citalopram treatments on serotonin 5-HT
pubmed: 11281975
Pan Y, Zhang W, Xia X, Kong L (2006) Effects of icariin on hypothalamic-pituitary-adrenal axis action and cytokine levels in stressed Sprague-Dawley rats. Biol Pharm Bull 29:2399–2403
pubmed: 17142971
Park E, Lee J, Jeong D, Han S, Jeon Y (2015) Natural killer cell activity in patients with major depressive disorder treated with escitalopram. Int Immunopharmacol 28:409–413
pubmed: 26177234
Perić I, Stanisavljević A, Gass P, Filipović D (2017) Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal gsh-dependent defense system and proinflammatory cytokines. Eur Arch Psychiatry Clin Neurosci 267:737–749
pubmed: 28474231
Perry V, Cunningham C, Holmes C (2007) Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7:161–167
pubmed: 17220915
Piletz J, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, DeVane C (2009) Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry 10:313–323
pubmed: 19921973
Ranjbar E, Shams J, Sabetkasaei M, M-Shirazi M, Rashidkhani B, Mostafavi A, Bornak E, Nasrollahzadeh J (2013) Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression. Nutr Neurosci 17:65–71
pubmed: 23602205
Rawdin B, Mellon S, Dhabhar F, Epel E, Puterman E, Su Y, Burke H, Reus V, Rosser R, Hamilton S, Nelson J, Wolkowitz O (2013) Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun 31:143–152
pubmed: 23201587
Remus J, Dantzer R (2016) Inflammation models of depression in rodents: relevance to psychotropic drug discovery. Int J Neuropsychopharmacol 19:1–13
Rosenblat J, McIntyre R (2018) Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials. J Affect Disord 227:219–225
pubmed: 29102836
Saad M, El-Sahar A, Sayed R, Elbaz E, Helmy H, Senousy M (2018) Venlafaxine mitigates depressive-like behavior in ovariectomized rats by activating the EPO/EPOR/JAK2 signaling pathway and increasing the serum estradiol level. Neurotherapeutics 16:404–415
pmcid: 6554373
Samuvel D, Jayanthi LD, Bhat NR, Ramamoorthy S (2005) A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci 25:29–41
pubmed: 15634764
pmcid: 6725216
Sanchez C, Reines E, Montgomery S (2014) A comparative review of escitalopram, paroxetine, and sertraline. Int Clin Psychopharmacol 29:185–196
pubmed: 24424469
pmcid: 4047306
Sangkuhl K, Klein T, Altman R (2009) Selective serotonin reuptake inhibitors pathway. Pharmacogenet Genom 19:907–909
Sankowski R, Mader S, Valdes-Ferrer S (2015) Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci 9:28
pubmed: 25698933
pmcid: 4313590
Silva-García O, Valdez-Alarcón J, Baizabal-Aguirre V (2014) The Wnt/β-catenin signaling pathway controls the inflammatory response in infections caused by pathogenic bacteria. Mediators Inflamm 2014:1–7
Silver H (2006) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283–304
Simon N, McNamara K, Chow C, Maser R, Papakostas G, Pollack M, Nierenberg A, Fava M, Wong K (2008) A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 18:230–233
pubmed: 17681762
Sluzewska A (1999) Indicators of immune activation in depressed patients. In: Dantzer R, Wollman E, Yirmiya R (eds) Cytokines, stress and depression. Advances in experimental medicine and biology, vol 461. New York, Springer, pp 59–73
Sluzewska A, Rybakowski J, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicv K (2006) Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 762:474–476
Sorrells S, Sapolsky R (2007) An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 21:259–272
pubmed: 17194565
Souza L, Filho C, de Gomes FLM, Goes A, Jesse C (2013) Depressive-like behaviour induced by an intracerebroventricular injection of streptozotocin in mice. Behav Pharmacol 24:79–86
pubmed: 23442845
Steiner J, Walter M, Gos T, Guillemin G, Bernstein H, Sarnyai Z et al (2011) Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflamm 8:94
Suarez E, Krishnan R, Lewis J (2003) The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 65:362–368
pubmed: 12764208
Sundberg I, Lannergård A, Ramklint M, Cunningham J (2018) Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. BMC Psychiatry 18:157
pubmed: 29843679
pmcid: 5975521
Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, Sanisoglu S, Yesilova Z, Ozmenler N, Ozsahin A, Sengul A (2007) Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007:1–6
Taniguti E, Ferreira Y, Stupp I, Fraga-Junior E, Doneda D, Lopes L, Rios-Santos F, Lima E, Buss Z, Viola G, Vandresen-Filho S (2019) Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. Brain Res Bull 146:279–286
pubmed: 30690060
Thameem Dheen S, Kaur C, Ling E (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14:1189–1197
pubmed: 17504139
Thomas J, Khanam R, Vohora D (2016) Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine pathway. Neurochem Int 99:103–109
pubmed: 27311540
Thomas J, Khanam R, Vohora D (2017) Activation of indoleamine 2,3-dioxygenase pathway by olanzapine augments antidepressant effects of venlafaxine in mice. Psychiatry Res 258:444–448
pubmed: 28911850
Todorović N, Filipović D (2017a) Prefrontal cortical glutathione-dependent defense and proinflammatory mediators in chronically isolated rats: modulation by fluoxetine or clozapine. Neuroscience 355:49–60
pubmed: 28499974
Todorović N, Filipović D (2017b) The antidepressant- and anxiolytic-like effects of fluoxetine and clozapine in chronically isolated rats involve inhibition of hippocampal TNF-α. Pharmacol Biochem Behav 163:57–65
pubmed: 29042248
Tomaz V, Chaves Filho A, Cordeiro R, Jucá P, Soares M, Barroso P, Cristino L, Jiang W, Teixeira A, de Lucena D, Macedo D (2020) Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. J Affect Disord 268:188–200
pubmed: 32174477
Trojan E, Chamera K, Bryniarska N, Kotarska K, Leśkiewicz M, Regulska M, Basta-Kaim A (2019) Role of chronic administration of antidepressant drugs in the prenatal stress-evoked inflammatory response in the brain of adult offspring rats: involvement of the NLRP3 inflammasome-related pathway. Mol Neurobiol 56:5365–5380
pubmed: 30610610
pmcid: 6614144
Tuglu C, Kara S, Caliyurt O, Vardar E, Abay E (2003) Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170:429–433
pubmed: 12955291
Vancassel S, Capuron L, Castanon N (2018) Brain kynurenine and BH4 pathways: relevance to the pathophysiology and treatment of inflammation-driven depressive symptoms. Front Neurosci 12:499
pubmed: 30140200
pmcid: 6095005
Vogelzangs N, Duivis H, Beekman A, Kluft C, Neuteboom J, Hoogendijk W, de Jongem SJP, Penninx B (2012) Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2:e79
pubmed: 22832816
pmcid: 3309556
Wang Q, Dong X, Wang Y, Liu M, Sun A, Li N, Lin Y, Geng Z, Jin Y, Li X (2017) Adolescent escitalopram prevents the effects of maternal separation on depression- and anxiety-like behaviours and regulates the levels of inflammatory cytokines in adult male mice. Int J Devl Neurosci 62:37–45
Wang Q, Dong X, Li N, Wang Y, Guan X, Lin Y, Kang J, Zhang X, Zhang Y, Li X, Xu T (2018) JSH-23 prevents depressive-like behaviors in mice subjected to chronic mild stress: effects on inflammation and antioxidant defense in the hippocampus. Pharmacol Biochem Behav 169:59–66
pubmed: 29684396
Wong D, Perry K, Bymaster F (2005) The discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 4:764–774
pubmed: 16121130
Xue J, Li H, Deng X, Ma Z, Fu Q, Ma S (2015) L-Menthone confers antidepressant-like effects in an unpredictable chronic mild stress mouse model via nlrp3 inflammasome-mediated inflammatory cytokines and central neurotransmitters. Pharmacol Biochem Behav 134:42–48
pubmed: 25937574
Yao L, Kan E, Lu J, Hao A, Dheen S, Kaur C, Ling E (2013) Toll-like receptor 4 mediates microglial activation and production of inflammatory mediators in neonatal rat brain following hypoxia: role of TLR4 in hypoxic microglia. J Neuroinflammation 10:23
pubmed: 23388509
pmcid: 3575244
Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J (2009) Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 33:722–726
pubmed: 19332097
Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Katsuki A, Atake K, Nakamura J (2013) Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. Hum Psychopharmacol 28:466–470
pubmed: 23813968
Young J, Bruno D, Pomara N (2014) A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord 169:15–20
pubmed: 25128861
Zareifopoulos N, Lagadinou M, Karela A, Kyriakopoulou O, Velissaris D (2020) Neuropsychiatric effects of antiviral drugs. Cureus 12(8):e9536
pubmed: 32905132
pmcid: 7465925
Zavvari F, Nahavandi A, Goudarzi M (2020) Fluoxetine attenuates stress-induced depressive-like behavior through modulation of hippocampal GAP43 and neurogenesis in male rats. J Chem Neuroanat 103:101711
pubmed: 31705954
Zhang J, Yao W, Hashimoto K (2016) Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol 14:721–731
pubmed: 5050398
pmcid: 5050398
Zhang X, Wang Q, Wang Y, Hu J, Jiang H, Cheng W, Ma Y, Liu M, Sun A, Zhang X, Li X (2016) Duloxetine prevents the effects of prenatal stress on depressive-like and anxiety-like behavior and hippocampal expression of pro-inflammatory cytokines in adult male offspring rats. Int J Dev Neurosci 55:41–48
pubmed: 27637928
Zhang K, Lin W, Zhang J, Zhao Y, Wang X, Zhao M (2020) Effect of Toll-like receptor 4 on depressive-like behaviors induced by chronic social defeat stress. Brain Behav 10(3):e01525
pubmed: 31945269
pmcid: 7066327
Zhao Y, Pan Y, Tang M, Lin W (2018) Blocking p38 signaling reduces the activation of pro-inflammatory cytokines and the phosphorylation of p38 in the habenula and reverses depressive-like behaviors induced by neuroinflammation. Front Pharmacol 9:511
pubmed: 29867510
pmcid: 5962764
Zhu C, Blakely R, Hewlett W (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31:2121–2131
pubmed: 16452991
Zou W, Feng R, Yang Y (2018) Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression. PLoS One 13:e0197267
pubmed: 29856741
pmcid: 5983476